Evotec AG (EVTCY) Stock Rating Upgraded by Zacks Investment Research

Evotec AG (NASDAQ:EVTCY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Monday. The brokerage currently has a $56.00 price objective on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 17.40% from the stock’s current price.

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Separately, DZ Bank AG reiterated a “sell” rating on shares of Evotec AG in a report on Thursday, August 17th.

Evotec AG (EVTCY) opened at 47.70 on Monday. Evotec AG has a one year low of $10.82 and a one year high of $52.82. The stock’s 50 day moving average is $43.88 and its 200 day moving average is $31.79. The stock has a market capitalization of $3.49 billion and a price-to-earnings ratio of 80.03.

Evotec AG (NASDAQ:EVTCY) last announced its quarterly earnings results on Thursday, August 10th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.03). The firm had revenue of $58.52 million during the quarter, compared to analyst estimates of $50.06 million.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://ledgergazette.com/2017/10/11/evotec-ag-evtcy-stock-rating-upgraded-by-zacks-investment-research.html.

About Evotec AG

Evotec AG is a drug discover

According to Zacks, “EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of drug candidates for partnering. Through research collaborations and proprietary projects They are providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries “

Separately, DZ Bank AG reiterated a “sell” rating on shares of Evotec AG in a report on Thursday, August 17th.

Evotec AG (EVTCY) opened at 47.70 on Monday. Evotec AG has a one year low of $10.82 and a one year high of $52.82. The stock’s 50 day moving average is $43.88 and its 200 day moving average is $31.79. The stock has a market capitalization of $3.49 billion and a price-to-earnings ratio of 80.03.

Evotec AG (NASDAQ:EVTCY) last announced its quarterly earnings results on Thursday, August 10th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.03). The firm had revenue of $58.52 million during the quarter, compared to analyst estimates of $50.06 million.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://ledgergazette.com/2017/10/11/evotec-ag-evtcy-stock-rating-upgraded-by-zacks-investment-research.html.

About Evotec AG

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply